Breast cancer(BC)is the most common malignant tumor and the main cause of death in women worldwide.With increased knowledge regarding tumor escape mechanisms and advances in immunology,many new antitumor strategies su...Breast cancer(BC)is the most common malignant tumor and the main cause of death in women worldwide.With increased knowledge regarding tumor escape mechanisms and advances in immunology,many new antitumor strategies such as nonspecific immunotherapies,monoclonal antibodies,anticancer vaccines,and oncolytic viruses,among others,make immunotherapy a promising approach for the treatment of BC.However,these approaches still require meticulous assessment and readjustment as resistance and modest response rates remain important barriers.In this article,we aim to summarize the most recent data available in BC immunotherapy to include the results of ongoing clinical trials and approved therapies used as monotherapies or in combination with conventional treatments.展开更多
基金Jacinto Convit World Organization Inc.and Fundación Jacinto Convit。
文摘Breast cancer(BC)is the most common malignant tumor and the main cause of death in women worldwide.With increased knowledge regarding tumor escape mechanisms and advances in immunology,many new antitumor strategies such as nonspecific immunotherapies,monoclonal antibodies,anticancer vaccines,and oncolytic viruses,among others,make immunotherapy a promising approach for the treatment of BC.However,these approaches still require meticulous assessment and readjustment as resistance and modest response rates remain important barriers.In this article,we aim to summarize the most recent data available in BC immunotherapy to include the results of ongoing clinical trials and approved therapies used as monotherapies or in combination with conventional treatments.
